盐酸克林霉素(Clindamycin Hydrochloride) - 药物靶点：50S subunit_在研适应症：急性支气管炎，喉炎，简单的皮肤和皮肤结构感染(uSSSI)_专利_临床

概要

基本信息

简介克林霉素于 1966 年首次由林可霉素制成，属于林可酰胺类，通过阻止细菌制造蛋白质起作用。克林霉素是一种抗生素药物，用于治疗多种细菌感染，包括骨髓炎（骨）或关节感染、盆腔炎、链球菌性咽喉炎、肺炎、急性中耳炎（中耳感染）和心内膜炎。它还可用于治疗痤疮和某些耐甲氧西林金黄色葡萄球菌 (MRSA) 的病例。与奎宁合用，可用于治疗疟疾。它可以通过口服、静脉注射以及作为乳膏或凝胶涂抹在皮肤或阴道内使用。

药物类型

小分子化药

别名

7(S)-Chloro-7-deoxylincomycin、7-CDL、C1indamycin Hydrochloride

+ [44]

靶点

50S subunit

作用方式

抑制剂

作用机制

50S subunit抑制剂(50S核糖体亚基抑制剂)

治疗领域

感染口颌疾病耳鼻咽喉疾病+ [4]

在研适应症

急性支气管炎喉炎简单的皮肤和皮肤结构感染(uSSSI)+ [18]

非在研适应症

恶性疟细菌性皮肤疾病

原研机构-

在研机构

Pfizer Inc.

Pfizer Japan, Inc.

华中药业股份有限公司

非在研机构

Taro Pharmaceuticals U.S.A., Inc.

Sanaria, Inc.

权益机构-

最高研发阶段批准上市

首次获批日期

(1969-10-01),

寻常痤疮厌氧菌感染革兰氏阳性细菌感染+ [1]

最高研发阶段(中国)批准上市

特殊审评-

登录后查看时间轴

结构/序列

分子式C18H34Cl2N2O5S

InChIKeyAUODDLQVRAJAJM-XJQDNNTCSA-N

CAS号21462-39-5

关联

201

项与盐酸克林霉素相关的临床试验

CTRI/2025/04/084990

/ Not yet recruiting临床3期

A multicenter, randomized, double-blind, parallel, three-arm, active- and placebo-controlled therapeutic equivalence study for the comparison of clindamycin + tretinoin/Verisfield gel (1+0.025)% with Acnatac /Meda gel [clindamycin + tretinoin (1+0.025)%] in the treatment of acne vulgaris. - Nil

开始日期2025-04-26

申办/合作机构-

NCT06702345

/ Not yet recruitingN/AIIT

Establishing a Clostridioides Difficile Controlled Human Infection Model

This study will investigate in healthy study subjects, the safety and tolerability of a controlled infection with Clostridioides difficile, a gut bacterium that can cause diarrhoea. It is also examined which dosing regimen (with or without antibiotic pretreatment) is required to induce mild symptoms (like diarrhoea) in the majority of study subjects and which microbiota and immunological factors influence this.
To investigate this, healthy adult study subjects will be asked to ingest capsules (pills) containing the Clostridioides bacterium.

开始日期2025-03-01

申办/合作机构

University of Oxford

[+2]

NCT06841003

/ Not yet recruiting临床3期

Laparoscopic Antibiotic Lavage to Prevent Intra-abdominal Abscess Formation in Complicated Appendicitis (ALPACA), a Multicenter Single-blinded RCT.

Appendicitis is one of the most common causes of acute surgical admission. Presently, two types of appendicitis are distinguished: complicated and uncomplicated (phlegmonous). Complicated appendicitis (CA) is defined as gangrenous and/or perforated appendicitis and/or appendicitis with an intra-abdominal or pelvic abscess. Laparoscopic appendectomy has become the preferential mode of surgical treatment. However, development of an intra-abdominal abscess (IAA) remains an important and clinically relevant complication following appendectomy, especially in complicated appendicitis. Although patients with complicated appendicitis receive postoperative intravenous antibiotics, the incidence of IAA remains considerable. The reported incidence of IAA in children and adults with CA is 7.9% - 24%. We recently reported an IAA rate of 12.3% after laparoscopic appendectomy for CA in our own institution. Patients with IAA are readmitted and treated with either antibiotics, image-guided percutaneous drainage, surgical reintervention, or a combination of these treatments. Furthermore, IAA represents a considerable burden for the healthcare system with high readmission rates and reinterventions, prolonged hospital stay, and therefore increased medical costs. Intra operative techniques aiming at more effective infection source control represent a clinically relevant area of investigation. Laparoscopic antibiotic lavage represents a promising concept in order to reduce intra-abdominal abscess formation. Antibiotic lavage is mainly known for the treatment of peritoneal dialysis associated peritonitis. Several studies show promising results of antibiotic peritoneal lavage on the incidence of surgical site infections (SSIs) including IAA in patients with CA. However, these studies were retrospective or conducted in a small number of patients who underwent an open appendectomy while high quality randomized controlled trials have not been performed yet.
The aim of the ALPACA study is to evaluate the effect of laparoscopic antibiotic peritoneal lavage with gentamicin / clindamycin for 3 minutes after appendectomy on the incidence of IAA in patients with CA.

开始日期2025-02-01

申办/合作机构

Stichting Spaarne Gasthuis

[+1]

100 项与盐酸克林霉素相关的临床结果

登录后查看更多信息

100 项与盐酸克林霉素相关的转化医学

登录后查看更多信息

100 项与盐酸克林霉素相关的专利（医药）

登录后查看更多信息

27,556

项与盐酸克林霉素相关的文献（医药）

2025-12-31·Future Science OA

A phytotherapeutic approach to hinder the resistance against clindamycin by MRSA: in vitro and in silico studies

Article

作者: Al-Mamoori, Farah ; Mayyas, Amal ; Al-Karablieh, Nehaya ; Al-Samydai, Ali ; Amr, Rula A. ; Zalloum, Waleed A ; Carradori, Simone ; Al-Tawalbeh, Deniz ; Al-Halaseh, Lidia Kamal ; Al Nsairat, Hamdi ; Aburjai, Talal

AIMS:

This study investigates the potential effects of essential oils (EOs) in enhancing the efficacy of clindamycin against Methicillin-resistant Staphylococcus aureus (MRSA) using in vitro and computer simulations. The research seeks to identify essential oils that exhibit synergistic activity with clindamycin and determine their potential key active components.

MATERIALS AND METHODS:

Essential oils commonly used in traditional medicine were tested for their antimicrobial activity against MRSA. The minimum inhibitory concentration (MIC) was determined using in vitro microdilution assays. A synergistic test with clindamycin was performed, and molecular docking studies evaluated the interaction between a key compound (trans-cinnamaldehyde) and MRSA protein.

RESULTS:

EOs from Cinnamomum verum, Rosmarinus officinalis, Salvia officinalis, and Thymus vulgaris demonstrated significant inhibitory and synergistic activities against MRSA, standard strain, and human clinical isolates. Gas Chromatography/Mass Spectroscopy identified trans-cinnamaldehyde, eucalyptol, and thymol as prominent antibacterial compounds. Molecular docking studies confirmed trans-cinnamaldehyde's strong binding to MRSA's AgrA protein, elucidating its enhanced efficacy.

CONCLUSION:

The study underscores the potential of plant-based therapies to augment the effectiveness of conventional antibiotics like clindamycin in combating MRSA and addressing antibiotic resistance by integrating traditional plant remedies with modern medical approaches.

2025-12-31·Emerging Microbes & Infections

Genomic islands and molecular mechanisms relating to drug-resistance in Clostridioides ( Clostridium ) difficile PCR ribotype 176

Article

作者: Soltesova, Anna ; Pituch, Hanna ; Kuijper, Ed ; Brajerova, Marie ; Balikova Novotna, Gabriela ; Prasad, Suhanya ; Novakova, Elena ; Zikova, Jaroslava ; Demay, Fanny ; Kovarovic, Vojtech ; Krutova, Marcela ; Smits, Wiep Klaas

OBJECTIVES:

To analyse characteristics of Clostridioides difficile PCR ribotype 176 clinical isolates from Poland, the Czech Republic and Slovakia with regard to the differences in its epidemiology.

METHODS:

Antimicrobial susceptibility testing and whole genome sequencing were performed on a selected group of 22 clonally related isolates as determined by multilocus variable-number tandem repeat analysis (n = 509). Heterologous expression and functional analysis of the newly identified methyltransferase were performed.

RESULTS:

Core genome multilocus sequence typing found 10-37 allele differences. All isolates were resistant to fluoroquinolones (gyrA_p. T82I), aminoglycosides with aac(6')-Ie-aph(2'')-Ia in six isolates. Erythromycin resistance was detected in 21/22 isolates and 15 were also resistant to clindamycin with ermB gene. Fourteen isolates were resistant to rifampicin with rpoB_p. R505K or p. R505K/H502N, and five to imipenem with pbp1_p. P491L and pbp3_p. N537K. PnimB^G together with nimB_p. L155I were detected in all isolates but only five were resistant to metronidazole on chocolate agar. The cfrE, vanZ1 and cat-like genes were not associated with linezolid, teicoplanin and chloramphenicol resistance, respectively. The genome comparison identified six transposons carrying antimicrobial resistance genes. The ermB gene was carried by new Tn7808, Tn6189 and Tn6218-like. The aac(6')-Ie-aph(2'')-Ia were carried by Tn6218-like and new Tn7806 together with cfrE gene. New Tn7807 carried a cat-like gene. Tn6110 and new Tn7806 contained an RlmN-type 23S rRNA methyltransferase, designated MrmA, associated with high-level macrolide resistance in isolates without ermB gene.

CONCLUSIONS:

Multidrug-resistant C. difficile PCR ribotype 176 isolates carry already described and unique transposons. A novel mechanism for erythromycin resistance in C. difficile was identified.

2025-12-31·Sustainable Environment

A review on the occurrence of antibiotic-resistant bacteria found in abattoir effluent from resource-limited settings: The necessity of a robust One Health framework

作者: Dinginya, Lawrance ; Jambwa, Prosper ; Majuru, Chenai Sipiwe ; Chari, Tawanda Ashley ; Machakwa, Jairus ; Mahlangu, Precious ; Gufe, Claudious ; Marowero, Sheunesu Theo ; Kadungure, Tafadzwa

A review.Abattoirs discharge untreated waste into surrounding bodies of water and the environment, which is extremely harmful to public health.Bacteria that cause disease, especially those resistant to antibiotics, may be present in these wastes.This review was carried out to provide a comprehensive overview of antibiotic-resistant microbes discovered in slaughterhouse wastes in resource-limited settings.Relevant research studies focussing on bacteria isolated from abattoir effluents in resource-limited settings and AMR patterns were searched on Google Scholar, PubMed, Web of Science, and African journals online.The studies showed that numerous bacteria were detected, such as Salmonella spp., Bacillus spp.,Shigella spp.,Escherichia coli, Pseudomonas aeruginosa, Citrobacter freundii, Proteus spp.,Streptococcus spp.,Yersinia spp. and Staphylococcus aureus.Several of these isolates were resistant to multiple antibiotics, including Penicillin, Vancomycin, Clindamycin, Erythromycin, Tetracycline, Ampicillin, Linezolid, Gentamycin, Ciprofloxacin, Ampicillin, Ceftriaxone, Imipenem, Cefotaxime, Chloramphenicol, Trimethoprim-sulfamethoxazole, Piperacillin-Tazobactam, Ceftazidime, Imipenem, and Meropenem.Lack of proper waste management practices due to financial constraints is the major cause of a high prevalence of resistant bacterial strains in abattoir effluents in resource-limited settings.Given the critical role that the environment plays in the spread and maintenance of antibiotic-resistant microorganisms, public health systems must strengthen One Health National Action plans applicable to abattoir effluents to successfully combat antibiotic resistance.

117

项与盐酸克林霉素相关的新闻（医药）

2025-07-10

·蒲公英Ouryao

一药企被停产整顿，去年底刚被处罚

转自：新疆药监局编辑：水晶近日，两地三药企有负面消息。7月7日，新疆药监局公布的两则行政处罚书显示，新疆麦迪森药业有限公司饮片分公司和新疆药都药业有限公司分别被没收违法所得、罚款、责令停产停业整顿，没收质量负责人等违法期间收入并处所获收入10%罚款的处罚。两家公司均因质量管理体系不能正常运行，药品生产过程控制记录不真实，未遵守药品生产质量管理规范被处罚。值得注意的是：新疆麦迪森药业有限公司饮片分公司，8个月前的2024年11月份因生产销售劣药刚被处罚。7月8日，据安徽药监局消息，在安徽药监部门的有因检查中，发现安徽联谊药业股份有限公司生产的盐酸克林霉素注射液存在质量安全风险，被暂停盐酸克林霉素注射液生产销售。1、新疆麦迪森药业有限公司饮片分公司2、新疆药都药业有限公司3、安徽联谊药业股份有限公司

2025-06-04

·PRNewswire

Aesculap Introduces XABO® Antibiotic-Impregnated Catheters for Hydrocephalus Treatment

CENTER VALLEY, Pa., June 4, 2025 /PRNewswire/ -- Aesculap, Inc. (Aesculap), the world's largest manufacturer of surgical instruments known for its innovations in neurosurgery, power systems and visualization, has launched XABO® Antibiotic-Impregnated Catheters in the U.S. market which will help to significantly reduce the risk of shunt infections in hydrocephalus patients.1 This innovative product is designed to improve treatment for both pediatric and adult patients who suffer from this condition. Hydrocephalus, characterized by excessive cerebrospinal fluid in the brain, affects over 1 million people in the United States. Shunt therapy, the most common treatment,2 often comes with the risk of infection,3 which impacts 7-15% of patients.4 These infections can impair quality of life, cognitive function and shunt survival.5 The XABO Antibiotic-Impregnated Catheters offer enhanced infection control, with clinical studies showing a two-thirds reduction in shunt infection rates as compared to standard catheters.4 The catheters continuously release antibiotics for a minimum of 38 days post-implantation,6 covering the critical period when patients are most vulnerable to infections.3,8-10 The XABO Antibiotic-Impregnated Catheter's unique packaging allows for extended sterility, up to 36 months, as well as being able to withstand temperatures up to 86°F without losing their effectiveness.6 The high potency of clindamycin hydrochloride and rifampicin impregnation allows for low antibiotic dosage release which may reduce allergic reactions and minimize the risk of resistance development. "We are excited to introduce the XABO Antibiotic-Impregnated Catheters, which represent a significant advancement in the treatment of hydrocephalus," said Bob Sowinski, Corporate Vice President, Aesculap. "This launch is key to our goal to improve patient outcomes and quality of life by reducing the incidence of shunt infections, a common and serious complication of hydrocephalus treatment." For more information, please visit our website. About Aesculap, Inc. Aesculap, Inc., a B. Braun company, is part of a 180-year-old global organization focused on meeting the needs of an ever-changing healthcare community. Through close collaboration with its customers, Aesculap provides advanced technologies for neurosurgery, general surgery and sterilization technologies. Aesculap continues a proud heritage of leadership and responsiveness as we strive to deliver products and services that improve the quality of patients' lives. For more information, call 800-282-9000 or visit aesculapusa.com. References: Fernández-Méndez R, Richards HK, Seeley HM, et al. Current epidemiology of cerebrospinal fluid shunt surgery in the UK and Ireland (2004-2013). Hydrocephalus Association. (2021). What is Hydrocephalus? | Hydrocephalus Association. . 2. Okamura Y, Maruyama K, Fukuda S, et al. Detailed standardized protocol to prevent cerebrospinal fluid shunt infection. J Neurosurg 2019:1–5. Okamura Y, Maruyama K, Fukuda S, et al. Detailed standardized protocol to prevent cerebrospinal fluid shunt infection. J Neurosurg 2019:1–5. Fernández-Méndez R, Richards HK, Seeley HM, et al. Current epidemiology of cerebrospinal fluid shunt surgery in the UK and Ireland (2004-2013). Vinchon M, Dhellemmes P. Cerebrospinal fluid shunt infection: risk factors and long-term follow-up. Childs Nerv Syst 2006;22(7):692–97. MIETHKE report. Data on file. Okamura Y, Maruyama K, Fukuda S, et al. Detailed standardized protocol to prevent cerebrospinal fluid shunt infection. J Neurosurg 2019:1–5. Borgbjerg BM, Gjerris F, Albeck MJ, Børgesen SE. Risk of infection after cerebrospinal fluid shunt: an analysis of 884 first-time shunts. Acta Neurochir (Wien). 1995;136(1-2):1-7. George R, Leibrock L, Epstein M. Long-term analysis of cerebrospinal fluid shunt infections. A 25-year experience. J Neurosurg. 1979;51(6):804-811. Wells DL, Allen JM. Ventriculoperitoneal shunt infections in adult patients. AACN Adv Crit Care. 2013;24(1):6-14. SOURCE Aesculap, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

合格传染病产品

2025-06-01

·梅斯医学

震惊！广东、河南近期发生两起一级甲等医疗事故！术中造影穿孔致死、青霉素未做皮试被判刑！基层诊疗为何总是出现“三素一汤”？

62岁老人胸痛到医院就诊手术后不幸身亡术中造影穿孔未及时发现省市两级均鉴定为一级甲等医疗事故5月21日晚，广东新闻频道“今日1线”栏目采访并播出了题目为“62岁老人胸痛到医院就诊手术后不幸身亡”的专题报道，事故经省市两级医学会鉴定认为：术中造影影像明显提示冠脉穿孔的情况下医方术者未尽观察义务，构成一级甲等医疗事故。据新闻报道内容显示，2023年9月27日，患者到广州医科大学附属第二医院心内科就诊，被诊断为“冠状动脉粥样硬化性心脏病”，于当天收入院做冠脉造影术和PCI术，术后不幸死亡。患者死亡后，家属在警察的陪同下完成了病历的封存。在新闻采访中，家属表示：“我们一再强调要求查明真相，但医院无视我们的诉求、冷处理，我们经历了给医院打电话没人接听、给主任发微信不回复的漫长过程，这个过程的煎熬给我们家属带来了无尽的痛苦。我们深知，再拖下去也不会有什么进展，于是我们委托律师开始了漫长的维权。”2024年11月21日，广州市医学会向患者家属发出首次医疗事故技术鉴定书，鉴定书内容显示：鉴定专家组认为，医方在对患者的诊疗过程中存在以下医疗过失行为:据《广州市卫生健康委员会关于XX投诉事项的答复函》及卫生行政执法文书《询问笔录》等资料显示:2023年9月27日17:30左右术者离开手术室向家属告知手术情况，当时手术未结束......;9月27日17:31之前患者未发生特殊情况，9月27日17:31患者出现渗液(考虑发生术中心脏压塞)，立即开始抢救.......鉴定专家组认真查阅造影影像资料获悉，9月27日17:19造影已显示造影剂向心包大量渗漏，提示出现冠脉穿孔。鉴定专家组综合现有的资料分析认为，9月27日17:19，造影已显示造影剂向心包大量渗漏，医方术者对患者术中病情观察存在疏漏，未能及时发现冠脉穿孔并进行处理。鉴定结论为，本例属于一级甲等医疗事故，医方承担次要责任。广医二院对首次鉴定的结果不服，提起了二次鉴定。2025年3月30，广东省医学会向患者家属发出二次鉴定医疗事故技术鉴定书，鉴定书显示：医方存在以下医疗过失:术中未及时发现冠脉穿孔。经认真查阅患者9月27日的造影影像资料，当日17:19造影显示造影剂向心包大量渗漏，提示出现冠脉穿孔，但医方未及时发现，影响了患者的抢救效果。患者家属的代理律师则表示：“17点19分就已经发生了穿孔，造影剂在渗漏，有十多分钟的抢救时间，医方却没有发现，这很明显有过错。”患者家属则表示：“回想起父亲病历里的死亡病例讨论记录，广医二院手术团队认定其‘手术操作规范，整个过程处理及时、得当’，让我不禁费解：如果真的‘手术操作规范，整个过程处理及时、得当’，省市两级医学会又怎么会认定你构成一级甲等医疗事故呢？手术出现重大失误引致患者死亡的后果本就是一件可怕的事情，更可怕的却是医院事后也没有复盘反思，那我父亲这条逝去的生命在医生们的眼中又算得上什么？”据悉，这起经省市两级医学会鉴定为一级甲等医疗事故的案件目前还在处理中。青霉素未做皮试，患者死亡河南一诊所医生被判刑一年4月28日，中国裁判文书网公布了另一起一级甲等医疗事故。根据案由显示，2022年11月17日21时，患者张某因嗓子疼、牙疼、耳朵痒到南阳市某诊所就诊，被告人吴某接诊，诊断为上呼吸道感染，给予输液治疗。输液时，吴某在左氧氟沙星100mL（含量0.2）静滴20mL时，在输液管中加入配制好的青霉素皮试液，观察患者有无不适，想当然以此代替青霉素皮试。后第二瓶输入“生理盐水250mL+青霉素800万+头孢曲松钠4g”10分钟至20分钟左右时，患者张某主诉难受、呛咳，吴某意识到患者对药物过敏，立即换掉液体，给予250mL葡萄糖水静滴，肾上腺素2支肌注，地塞米松10mg肌注，葡萄糖酸钙20mL加盐水100mL静滴，几分钟后患者呼吸、心跳骤停，医方给予心肺复苏并拨打120。22时05分，患者由120救护车转至南阳市中心医院抢救，虽经心肺复苏、心电监护、气管插管、急救药物应用等抢救，患者还是于23时02分宣告临床死亡。患者死亡后，此案被提起诉讼，经河南省医学会鉴定：1、医方给予患者输注青霉素前，未做皮试。在注射用左氧氟沙星中滴入两滴青霉素代替皮试的行为，不符合临床用药规范。2、医方将青霉素与头孢曲松混合应用，违反药物说明书的规定。3、医方对患者的病情诊断为上呼吸道感染，同时应用三种抗生素（其中包含两种β-内酰胺类抗生素）欠妥当。根据患者用药情况，突发病情变化、临床表现及死亡经过等临床资料，专家组综合分析认为：患者符合药物过敏性休克致呼吸循环衰竭死亡。医方过失行为在患者损害后果中起主要作用，故医方应承担主要责任。根据《医疗事故分级标准（试行）》，本案构成一级甲等医疗事故。后经法院另查明，被告人吴某于2019年9月24日取得执业医师资格，未参加2020年5月卧龙区卫健委组织的抗菌药物处方权或者抗菌药物调剂资格的培训和考核。至案发时，没有依法取得“抗菌药物处方权或者抗菌药物调剂资格”。2023年11月29日，吴某与患者家属签署协议，由吴某赔偿丧葬补助金、抚恤金等费用200000元（已支付），家属不再追究吴某任何责任，并对其行为表示谅解。最终，法院判决：综合考虑被告人吴某的犯罪性质、犯罪后果、医疗事故责任、处置违规情况及自首、认罪认罚、赔偿损失并取得谅解等量刑情节，依照《中华人民共和国刑法》、《中华人民共和国刑事诉讼法》，被告人吴某犯医疗事故罪，判处有期徒刑一年，缓刑一年。PCI术中穿孔需及时发现基层诊疗的不规范令人担忧为什么总是动不动就“三素一汤”？近期发生的这两起一级甲等医疗事故给我们带来的教训都很大，其实大概率都可以避免。广东一名心内医生发表评论认为：“造影和PCI术中穿孔，渗漏，是完全可以及时发现的，这是我们心内科偶尔会遇到的情况，识别穿孔不就那些吗？直接证据为：1.冠脉造影可见到造影剂外溢；2.心包内造影剂滞留影；3.术后超声心动图见新发心包积液；4.X线透视下发现心影增大、心脏搏动减弱或消失伴心影外缘透亮带。说到底还是技术不精呀。”查阅资料可知，冠脉穿孔是由于球囊或支架不匹配(扩张导管尺寸过大，尤其是当球囊动脉比>1.2:1或半顺应性球囊持续高压力膨胀时)导致的血管壁破裂引起，或由于导丝在冠脉内无意移动导致。在PCI过程中，冠脉穿孔的发生率低于0.5%，由此引起的心包填塞的发生率约为0.12%，概率还是较低的。冠脉穿孔可以是明显的漏血或局部渗血，表现为造影剂直接漏入心包或局部，也可以是末梢血管不易发现的小的渗漏；少数情况下冠状动脉穿孔在术中未能发现，术后数十分钟至数小时后由于少量持续出血导致心包填塞，及时诊断并积极治疗是降低患者病死率的关键。像上文中的案例，穿孔发现不及时，医生也确实有责任，这真的考验医生的医术。在另一起青霉素未做皮试致死的案例中，我们深为基层医疗的不规范诊疗感到担忧。一看到案例中的信息，笔者就浑身颤抖，一个上呼吸道感染，竟然用了三种抗生素，连β-内酰胺类抗生素都用了，怎么会不出意外呢？只是或早或晚的问题。对此，安徽皖北一名医生就表示：“部分诊所这样处理，效果也立竿见影，老百姓就喜欢这样的处方，由于青霉素易过敏，头孢需皮试，左氧有胃肠道反应，于是，现在他们又选了个有效又折中的方子，用克林霉素或林可霉素，甚至有的诊所能开出极其广谱的亚胺培南！也别管培养什么超级耐药菌了，老百姓说好那就是好，你三天治不好病，你就是庸医！诊所医生开药都特别疯狂。”在患者一味求效果、求立竿见影的现状下，可以想象，基层的不规范用药肯定很难改变，毕竟没效果就没患者，但笔者还是要劝诫基层医生多注意药物配伍的安全性！真的深深担忧，基层的现状就是这样，不验血、不拍片做CT，甚至各种抗原检测试剂也没有，发烧咳嗽无法精准诊断，为了省事求全面，更为了追求效果，三素一汤（抗生素、激素、抗病毒，以及糖和盐）已经成了标配，至于其他的，老百姓不管，老百姓看中的只会是效果。可一旦真的出现了严重问题，像上文中出现了死亡，患者和诊所又都无法承担沉重的代价，说到底这是一个概率问题，医生和患者都心存侥幸，都在赌，赌患者没事，赌自己是命运眷顾的人。撰文 | 阿拉斯加宝编辑 | 阿拉斯加宝● 重磅！63%县医院达到三级水平！成了三级医院，为何还是难留病人？网友：评级上去了，医术改变不大，收费却提高了，很难有吸引力●按掉闹钟多睡会儿or一响就起床？「再睡几分钟让人起床时更清醒，认知表现更佳」vs「频繁打断睡眠、反应更迟钝」，两项研究吵翻了！●热议！取鱼刺花了85元，患者嫌贵，要投诉！网友：我曾在美国拔鱼刺花了1万元，为何这么不知足？鱼刺位置决定收费，医生的价值要被尊重版权说明：梅斯医学（MedSci）是国内领先的医学科研与学术服务平台，致力于医疗质量的改进，为临床实践提供智慧、精准的决策支持，让医生与患者受益。欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。点击下方「阅读原文」立刻下载梅斯医学APP！

诊断试剂

100 项与盐酸克林霉素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D02132	盐酸克林霉素	G01AA10 J01FF01 D10AF01	DB01190

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
急性支气管炎	日本	Pfizer Japan, Inc.	1970-11-20
喉炎	日本	Pfizer Japan, Inc.	1970-11-20
简单的皮肤和皮肤结构感染(uSSSI)	日本	Pfizer Japan, Inc.	1970-11-20
中耳炎	日本	Pfizer Japan, Inc.	1970-11-20
咽炎	日本	Pfizer Japan, Inc.	1970-11-20
肺炎	日本	Pfizer Japan, Inc.	1970-11-20
脓皮症	日本	Pfizer Japan, Inc.	1970-11-20
猩红热	日本	Pfizer Japan, Inc.	1970-11-20
继发感染	日本	Pfizer Japan, Inc.	1970-11-20
鼻窦炎	日本	Pfizer Japan, Inc.	1970-11-20
扁桃体炎	日本	Pfizer Japan, Inc.	1970-11-20
腹腔脓肿	美国	Pfizer Inc.	1970-02-22
复杂的皮肤和软组织感染	美国	Pfizer Inc.	1970-02-22
感染	美国	Pfizer Inc.	1970-02-22
腹腔感染	美国	Pfizer Inc.	1970-02-22
生殖道感染	美国	Pfizer Inc.	1970-02-22
呼吸道感染	美国	Pfizer Inc.	1970-02-22
寻常痤疮	-	-	1969-10-01
厌氧菌感染	-	-	1969-10-01
革兰氏阳性细菌感染	-	-	1969-10-01

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
恶性疟	临床1期	加蓬	Sanaria, Inc.	2014-07-01
细菌性皮肤疾病	临床阶段不明	美国	Pfizer Inc.	2012-01-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03261830 (Therapeutic Level I, CTgov)	临床4期	手术伤口感染 \| 肱骨骨折	160	Cefazolin+Clindamycin (Pre-operative Antibiotics)	憲繭築餘膚築選廠窪醖 = 壓鹽鏇襯願膚蓋顧獵壓顧鬱獵艱範餘鏇觸壓遞 (憲淵構醖鏇繭糧蓋壓襯, 衊夢淵選遞構築構網製 ~ 鬱壓夢窪齋構網艱襯鏇) 更多	-	2024-08-09
				Saline (Saline Placebo)	憲繭築餘膚築選廠窪醖 = 繭憲憲積網願願壓餘廠顧鬱獵艱範餘鏇觸壓遞 (憲淵構醖鏇繭糧蓋壓襯, 糧餘築鏇衊遞蓋鏇衊鬱 ~ 蓋壓鬱糧襯壓製構壓鏇) 更多
AAAAI2024	N/A	特应性皮炎	-	antistaphylococcal drugs (Group 1 (positive initial BC for S.aureus))	鏇鏇選簾鏇壓鬱鹽積鑰(範衊夢獵構築構夢窪鹹) = 製夢壓醖鬱窪遞襯鹽繭簾壓膚夢夢鬱觸餘蓋齋 (網顧廠網憲膚壓觸餘壓 ) 更多	-	2024-02-23
				antistaphylococcal drugs (Group 2 (negative BC for S.aureus))	鏇鏇選簾鏇壓鬱鹽積鑰(範衊夢獵構築構夢窪鹹) = 鑰憲遞夢壓觸艱獵膚醖簾壓膚夢夢鬱觸餘蓋齋 (網顧廠網憲膚壓觸餘壓 ) 更多
NCT03945357 (RINSE, CTgov)	临床3期	腹疝 \| 感染	250	Normal saline (Saline Irrigation)	範糧積餘構餘網鏇衊艱 = 遞醖憲艱糧積鹽齋壓壓憲鹹構壓築蓋蓋獵衊蓋 (艱構鹹願範築願窪鑰艱, 醖鏇衊簾觸遞積憲膚願 ~ 壓簾餘觸齋壓壓衊製窪) 更多	-	2023-08-24
				Gemcitabine+clindamycin (Antibiotic Irrigation)	範糧積餘構餘網鏇衊艱 = 網醖鏇齋廠選鬱選膚築憲鹹構壓築蓋蓋獵衊蓋 (艱構鹹願範築願窪鑰艱, 衊築選選壓觸網壓壓鏇 ~ 選淵遞窪齋網遞觸齋鏇) 更多
NCT02579161 (CTgov)	临床3期	肾结石	98	Fluoroquinolones+cephalosporins+Gentamicin+Ampicillin+Clindamycin (Antibiotics for a 24 Hour Period)	製願選範願築窪鬱願積 = 遞憲築窪遞醖範憲簾築醖夢蓋餘窪襯齋觸鏇壓 (衊鏇襯憲膚艱膚選鏇製, 鹽艱遞願觸艱鹽襯簾簾 ~ 顧遞淵鹽製餘窪鹽製選) 更多	-	2023-03-14
				Fluoroquinolones+cephalosporins+Gentamicin+Ampicillin+Clindamycin (Continued Antibiotics)	製願選範願築窪鬱願積 = 艱鏇膚鑰範齋廠選鹽襯醖夢蓋餘窪襯齋觸鏇壓 (衊鏇襯憲膚艱膚選鏇製, 醖觸鏇衊網願襯鏇構艱 ~ 選願襯衊積遞鹽廠衊範) 更多
ARVO2022	N/A	弓形虫病一线	19	Intravitreal Clindamycin	網觸鏇夢蓋鬱艱壓夢鹹(鑰蓋廠夢鏇鏇遞蓋餘簾) = 顧製糧壓簾繭選顧繭觸衊窪鬱遞網窪積顧獵構 (衊淵蓋築夢鹽襯獵蓋醖 ) 更多	-	2022-05-01
NCT03478163 (CTgov)	临床4期	产后出血 \| 子宫内膜炎	11	antibiotics (Control)	齋網製窪選簾齋膚憲壓 = 齋選願襯鑰獵範選衊鏇獵簾構夢願膚艱獵蓋襯 (鏇糧築鹹鹽膚遞獵糧願, 鏇遞遞範餘鏇艱築鑰顧 ~ 淵膚積範衊糧製遞獵鑰) 更多	-	2021-10-07
				CeFAZolin 1000 MG+Clindamycin 900 MG in 6 ML Injection (Antibiotics)	齋網製窪選簾齋膚憲壓 = 齋築鏇夢積糧簾遞蓋醖獵簾構夢願膚艱獵蓋襯 (鏇糧築鹹鹽膚遞獵糧願, 壓網遞構廠淵艱鏇鑰構 ~ 積鬱製積夢蓋遞蓋構鏇) 更多
AAAAI2021	N/A	-	9	Direct Antibiotic Challenges (Telehealth A&I consultation)	觸鏇觸窪顧鑰醖鑰選築(獵齋顧憲顧夢遞膚網獵) = 壓網遞艱鑰鹹衊顧鑰鹽遞簾齋鬱齋夢構襯簾遞 (醖範膚製積簾選淵蓋簾 )	积极	2021-02-01
NCT02730962 (CTgov)	临床2期	代谢综合征 \| 糖尿病前期	12	Fecal Microbiota Transplantation+Neomycin+Clindamycin+Vancomycin (Antibiotics Prior to FMT)	鹹鹹鬱艱範淵鹽糧範願(衊壓廠範餘築餘鏇繭顧) = 餘築艱製襯獵網遞積簾餘壓壓範鹽顧糧遞選糧 (衊觸鬱顧鹽遞憲蓋鹽憲, 0.5) 更多	-	2020-11-20
				Fecal Microbiota Transplantation (Placebo Prior to FMT)	鹹鹹鬱艱範淵鹽糧範願(衊壓廠範餘築餘鏇繭顧) = 鬱衊鏇糧餘選顧醖鹹膚餘壓壓範鹽顧糧遞選糧 (衊觸鬱顧鹽遞憲蓋鹽憲, 0.5) 更多
NCT02515305 (CTgov)	临床3期	寻常痤疮	890	Clindamycin+Benzoyl Peroxide (Test Product)	廠糧糧繭膚鏇範膚醖蓋(憲蓋構遞膚齋淵鹽夢顧) = 鬱簾選構齋艱齋範網觸選積範窪鹹鑰鹹醖鏇膚 (遞襯構鹹憲範網網獵築, 29.823) 更多	-	2020-11-16
				Clindamycin+Benzoyl Peroxide (Reference Product)	廠糧糧繭膚鏇範膚醖蓋(憲蓋構遞膚齋淵鹽夢顧) = 鬱獵鹽膚壓憲醖鏇簾遞選積範窪鹹鑰鹹醖鏇膚 (遞襯構鹹憲範網網獵築, 26.926) 更多
NCT03522441 (CTgov)	临床3期	寻常痤疮	1,125	Clindamycin (Clindamycin 1% Gel (Akorn Pharmaceuticals))	簾艱廠選壓壓憲淵膚網(繭遞網艱鬱獵繭憲夢鏇) = 衊齋遞壓壓鹹蓋壓遞廠齋鑰襯膚選衊廠襯憲醖 (廠觸觸簾築願網獵淵窪, 28.002) 更多	-	2020-10-05
				Clindamycin (Clindamycin 1% Gel (Greenstone LLC))	簾艱廠選壓壓憲淵膚網(繭遞網艱鬱獵繭憲夢鏇) = 網窪糧窪繭艱壓餘襯鹹齋鑰襯膚選衊廠襯憲醖 (廠觸觸簾築願網獵淵窪, 27.19) 更多